GlassScriptPhysician profile
Asif Siddiq
NPI 1467763078
$1,725.37
in general payments reported to CMS, 2019-2025
33 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $237 · 2021: $291 · 2022: $85.13 · 2023: $221 · 2024: $366 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $299.93 | 2020-2021 | |
| Lilly USA, LLC | $144.15 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $128.07 | 2019-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $119.13 | 2024-2025 | |
| Novo Nordisk INC | $109.20 | 2020-2025 | Rybelsus, Ozempic |
| Amgen INC. | $98.18 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $62.57 | 2021-2024 | Proclaim, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $60.09 | 2024-2025 | Airsupra |
| Abbvie INC. | $58.00 | 2020-2025 | Vraylar |
| Insulet Corporation | $56.12 | 2024-2025 | Omnipod |
| Scilex Pharmaceuticals INC. | $54.06 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $53.73 | 2019 | |
| Madrigal Pharmaceuticals | $51.11 | 2024-2025 | Rezdiffra, Resmetirom |
| Genentech USA, INC. | $40.30 | 2020 | |
| Horizon Therapeutics Plc | $32.88 | 2022-2023 | Tepezza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alvogen INC | $28.08 | 2023 | Teriparatide |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.12 | 2019-2020 | |
| Radius Health, INC. | $25.79 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.71 | 2021 | |
| Ascendis Pharma Endocrinology INC | $23.95 | 2024 | |
| Ionis Pharmaceuticals, INC. | $22.94 | 2025 | Tryngolza |
| Corcept Therapeutics | $21.49 | 2025 | Korlym |
| Alexion Pharmaceuticals, INC. | $20.63 | 2025 | Strensiq |
| Amphastar Pharmaceuticals, INC. | $20.55 | 2024 | |
| Ibsa Pharma INC. | $18.61 | 2020 | |
| Medtronic, INC. | $17.65 | 2023 | Accurian |
| Recordati_rare_diseases_inc. | $16.46 | 2024 | Isturisa, Signifor Lar |
| Merck Sharp & Dohme LLC | $16.26 | 2019 | |
| Zealand Pharma US, INC. | $15.39 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.29 | 2024 | |
| Medtronic Minimed, INC. | $14.75 | 2020 | |
| Idorsia Pharmaceuticals US INC | $14.26 | 2023 | Quviviq |
| Pfizer INC. | $12.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asif Siddiq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.